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Conclusion. Although excellent rates of biochemical response (80.7%) in patients treated with salvage EBRT, biochemical failure-
free survival at 5 years was 55%. It is essential to analyze strategies such as combination with antiandrogen treatment or increase
doses to improve results with actual treatments.
http://dx.doi.org/10.1016/j.rpor.2013.03.519
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Purpose. The role of androgen-deprivation therapy (ADT) is poorly deﬁned in the era of dose-escalated radiotherapy in
intermediate-risk prostate cancer patients. The purpose of this study is to evaluate the effect of short-term androgen-deprivation
therapy on cancer control in intermediate-risk prostate cancer patients treated with high-dose radiotherapy (HDRT).
Methods and materials. The present retrospective study comprised 185 NCCN intermediate-risk prostate cancer patients at 3 insti-
tutions treated with 3-dimensional conformal RT (76Gy) from 2002 to 2010, including 40 patients receiving ADT 2–6 months
before HDRT (none of them longer than 9 months). We deﬁned biochemical failure according to the Phoenix deﬁnition of bio-
chemical free survival (BFS). The Kaplan–Meier method and Log-rank test was used to estimate the BFS and overall survival (OS).
Cox proportion hazards regression model were performed.
Results. The minimum follow-up was 24 months, and the median follow-up was 64.6 months. For ADT patients vs. no ADT
patients, the 7-year BFS rate was 96% vs. 88% (p=0.124) and the 7-year OS rate was 92% vs. 91% (p=0.373). On Cox proportion
hazards regression model, after adjusting for pre-treatment PSA, Gleason score and T stage, the addition of ADT to HDRT did
not reveal a signiﬁcant effect on BFS (HR, 0.176; 95% CI, 0.023–1.330; p=0.092). Gleason score 7=4+3 was signiﬁcantly associated
with BFS (HR, 3.869; 95% CI, 1.267–11.813; p=0.018) compared with Gleason score ≤6. The 7-year BFS rate in Gleason 7=4+3 vs.
Gleason ≤6 was 75% vs. 94% respectively (p=0.03).
Conclusion. The addition of ADT did not signiﬁcantly improve BFS survival in intermediate-risk prostate cancer patients. The
result of this study requires testing in prospective randomized trials.
http://dx.doi.org/10.1016/j.rpor.2013.03.520
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Introduction. Dose escalation with radiotherapy is recommended in intermediate risk and high risk prostate cancer. Prostate
cancer also beneﬁts from hypofractionation schemes, according to the linear quadratic model due to its low alpha/beta.
Purpose. To analyze acute toxicity secondary to radical treatment of high and intermediate risk prostate adenocarcinoma using
VMAT with simultaneous integrated boost technique.
Material and methods. Between January 2011 and December 2012, 32 patients were treated in our department, using VMAT and
simultaneous integrated boost. D’Amico criteria were used to classify patients into risk groups. Radiation scheme used was 33
sessions of 2.25Gy (total dose 74.25Gy) to the prostate, 1.8Gy per fraction to seminal vesicles, and 1.64Gy per fraction to the pelvis
if the estimated risk of affection was greater than 15%. Daily Image-guided “Cone Beam” was performed. We hereby present a
descriptive analysis of the patients and analysis of acute toxicity (RTOG toxicity scale).
Results. Mean age was 69.24 years (60–78), intermediate 5 patients (15.6%), high risk 25 patients (78.1%). All patients received
complete androgen blockade. Volumes of treatment in 1 patient (3.1%) only prostate, 20 patients (62.5%) prostate +vesicles, and 11
patients (34.4%) prostate +pelvis + vesicles.Dosimetric values (median) of thePTV (planning target volume). ProstateD2%79.16Gy,
D50% 76.29Gy, D98% 71.3Gy. PTV prostate +vesicles: D2% 78.52Gy, D50% 73.69Gy, D98% 58.7Gy. PTV pelvis +prostate +vesicles:
D2% 77.36Gy, D50% 55.97Gy, D98% 51.14Gy. Maximum toxicity recorded was grade 2. Urinary G2, 2 patients (6.3%); frequency
G2, 8 patients (25%); dysuria G2, 4 patients (12.5%), asthenia G1, 5 patients (15.6%); ﬂushes G2, 2 patients (6.3%); proctitis G2, 1
patient (3.1%).
Conclusions. Treatment of prostate cancer with simultaneous integrated boost with VMAT provides optimal coverage to different
target volumes while acute toxicity remains acceptable.
http://dx.doi.org/10.1016/j.rpor.2013.03.521
